Blauvelt, A., R. Warren, K. Reich, F. Brock, F. Fierens, V. Ciaravino, and M. Lebwohl. “Durability of DLQI Improvements Among Patients With Moderate to Severe Plaque Psoriasis Treated With Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s80, doi:10.25251/skin.4.supp.80.